THA903 is a small, water-soluble, 11-amino acid peptide derived from hannalgesin, a neurotoxin isolated from King Cobra (Ophiophagus hannah) venom, which is both toxic and also a potent analgesic.
The development of THA903 was the result of optimization discovery work conducted at the National University of Singapore (NUS). The structural modeling and optimization work enabled the peptide to maintain hannalgesin’s potent analgesic properties without its neurotoxic activity.
Although the mechanism of action of TH903 has not been fully elucidated, it is thought that it operates via a nNOS-dependent mechanism which results in the activation of the endogenous enkephalin system. This is a novel antinociceptive mechanism of action. The pharmacological and toxicity profiles of THA903 have been evaluated extensively in relevant preclinical models that demonstrated its analgesic properties and a preliminary safety.
TH903 proposed utility is in the areas of chronic nociceptive (Ca-related or other) and inflammatory pain.
THA903 is also positioned in a project labeled by the pole Eurobiomed for the treatment of acute pain. (news may 2011)